7,439 Shares in Alkermes plc $ALKS Acquired by Pzena Investment Management LLC

Pzena Investment Management LLC bought a new position in Alkermes plc (NASDAQ:ALKS) in the second quarter, according to its most recent filing with the SEC. The firm bought 7,439 shares of the company’s stock, valued at approximately $213,000.

A number of other institutional investors also recently bought and sold shares of ALKS. Twin Tree Management LP acquired a new stake in Alkermes in the 1st quarter worth approximately $29,000. Armstrong Advisory Group Inc. acquired a new stake in Alkermes in the 2nd quarter worth approximately $29,000. Brooklyn Investment Group boosted its stake in Alkermes by 1,071.1% in the 1st quarter. Brooklyn Investment Group now owns 1,054 shares of the company’s stock worth $35,000 after purchasing an additional 964 shares in the last quarter. Quantbot Technologies LP lifted its stake in Alkermes by 54.5% during the 1st quarter. Quantbot Technologies LP now owns 1,091 shares of the company’s stock valued at $36,000 after acquiring an additional 385 shares during the period. Finally, Fifth Third Bancorp lifted its stake in Alkermes by 54.4% during the 1st quarter. Fifth Third Bancorp now owns 1,479 shares of the company’s stock valued at $49,000 after acquiring an additional 521 shares during the period. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have commented on ALKS shares. Needham & Company LLC set a $43.00 price objective on shares of Alkermes in a research note on Tuesday, September 9th. Royal Bank Of Canada upgraded shares of Alkermes from a “sector perform” rating to an “outperform” rating and lifted their price objective for the company from $42.00 to $44.00 in a research note on Friday, September 26th. UBS Group upgraded shares of Alkermes from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $33.00 to $42.00 in a research note on Tuesday, June 17th. JPMorgan Chase & Co. lifted their price objective on shares of Alkermes from $34.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, September 9th. Finally, The Goldman Sachs Group started coverage on shares of Alkermes in a research note on Tuesday, July 15th. They set a “buy” rating and a $43.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Alkermes Price Performance

ALKS opened at $32.17 on Tuesday. The firm has a fifty day moving average price of $28.76 and a 200 day moving average price of $29.12. Alkermes plc has a 1 year low of $25.17 and a 1 year high of $36.45. The stock has a market cap of $5.31 billion, a P/E ratio of 15.47, a P/E/G ratio of 1.69 and a beta of 0.54.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Tuesday, July 29th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.10. Alkermes had a net margin of 23.15% and a return on equity of 24.86%. The firm had revenue of $390.66 million during the quarter, compared to analysts’ expectations of $343.20 million. During the same period in the previous year, the business posted $1.16 EPS. The business’s revenue was down 2.1% compared to the same quarter last year. Alkermes has set its FY 2025 guidance at 1.030-1.210 EPS. Equities analysts expect that Alkermes plc will post 1.31 EPS for the current year.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.